The effect of 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (cPTIO), a nitric oxide (NO) scavenger that yields nitrogen dioxide (NO 2 ) in a rat endotoxemia model was investigated. Endotoxin (lipopolysaccharide [LPS]) increased NO synthase (NOS) activity and inducible NOS expression measured in lung and plasma levels of nitrite/nitrate, 6-oxoprostaglandin (PG) F 1a , thromboxane B 2 , and PGF 2a . Infusion of cPTIO significantly reduced LPS-induced mean arterial blood pressure decline and mortality and selectively reduced LPSinduced 6-oxo-PGF 1a plasma levels and prostacyclin synthase (PGIS) activity measured in the lung and aorta. In vitro, PGIS activity in aorta rings was not modified by SNAP (NO donor), cPTIO slightly inhibited the enzyme but not in the presence of L-N G -monomethyl arginine, and SNAP in combination with cPTIO significantly inhibited PGIS. Thus, cPTIO may be beneficial in endotoxic shock because of NO scavenging and PGIS inactivation, which could be mediated by NO 2 .
in endothelial cells and may be induced by the inflammatory cytokines [10, 11] . Homolytic fission of peroxynitrous acid, formed by protonation of peroxynitrite, yields nitrogen dioxide (NO 2 ) and hydroxyl radical [12, 13] . Peroxynitrite inactivates PGIS by nitration of an active site-related tyrosine [14] .
We observed [1] that NO was involved in the partial inactivation of PGIS during the exposure of endothelial cells to interleukin (IL)-1b. The implication of NO on PGIS inhibition in human endothelial cells exposed to IL-1b was based on the fact that L-N G -monomethyl arginine (L-NMMA), an NO synthase (NOS) inhibitor, abrogated the inhibitory effect of IL-1b [1] . Indeed, 5-amino-3-(4-morpholinyl)-1,2,3-oxadiazolium, which releases both NO and superoxide anion and acts as a source of peroxynitrite, inactivated PGIS in both resting and IL-1b-treated endothelial cells [1] .
2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (cPTIO) is an NO scavenger that reacts with NO to yield NO 2 plus 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl (cPTI) [15] . It impairs the vasorelaxation induced by acetylcholine [16] and exhibits a potent therapeutic value in a rat model of endotoxic shock [17] . The fact that inactivation of PGIS caused by the treatment of endothelial cells with IL1b was significantly enhanced by the presence of cPTIO during exposure to IL-1b argues against a direct effect of NO on PGIS activity. Nitration of tyrosyl residues by NO 2 is possible through the formation of tyrosyl radicals [18] [19] [20] . Collectively, our previous results with human endothelial cells in culture with L-NMMA and cPTIO were consistent with the concept that the inactivation of the PGIS caused by the incubation with IL-1b was mediated by NO 2 [1] .
In the present investigation, we attempted to extend our previous in vitro observations, to test the hypothesis that effectively there is an NO 2 -dependent inactivation of PGIS in vivo under inflammatory conditions that could be potentiated by cPTIO. The inhibitory action of cPTIO on PGIS could also contribute to the beneficial effect of cPTIO observed in endotoxic shock.
Methods
cPTIO and cPTI synthesis. cPTIO potassium salt was synthesized by modification of a method described elsewhere [15] . The starting compound, 2,3-hydroxylamino-2,3-dimethylbutane [21] , was condensed at room temperature with 4-formilbenzoic acid in the presence of aqueous NaHCO 3 , leading to the intermediate compound 4-(1,3-dihydroxy-4,4,5,5-tetramethyltetrahydro-2-imidazolyl)benzoic acid. The latter compound was oxidized in dimethylformamide solution, using PbO 2 as reagent and yielding cPTIO in the acid form as a deep-blue crystalline solid (melting point [m.p.], 188ЊC decomposition). The corresponding potassium salt was synthesized in high yield by dissolving this product in anhydrous dichloromethane and by neutralizing it with an alcohol solution of potassium tert-butoxide. cPTIO potassium salt was obtained as a high-purity blue precipitated solid (m.p., 215ЊC decomposition). No further purification steps were needed. cPTI was obtained from cPTIO by reaction with NO [15] . NO gas was bubbled though a phosphate-buffered (pH 7.4) cPTIO solution, and cPTI was purified by silica-gel column chromatography. Structures were confirmed by infrared, nuclear magnetic resonance, and electron spin resonance spectral information and by elementary analysis data. Purity was checked by thin-layer chromatography and by nonaqueous acidimetric titration.
Mean arterial blood pressure (MAP) measurement. The study was done with male Sprague-Dawley rats weighing 250-300 g. The animals received a standard diet and water ad libitum. All animals were anesthetized intraperitoneally with sodium pentobarbital (60 mg/kg); anesthesia was maintained by supplementary injections of pentobarbital as required. The trachea was cannulated to facilitate breathing during experimentation. The left carotid artery was cannulated and connected to a pressure transducer (Transpac IV; Abbott) for MAP measurement that was displayed on a data acquisition system (Acq Knowledge 3.2; Biopac Systems) on a PC computer. The right femoral vein was cannulated for drug administration. After completion of the surgical procedure, MAP was allowed to stabilize for 15 min.
Experimental design. After the stabilization period, administration of c-PTIO (1.7 mg/kg/min: 0.025 mL/min), cPTIO-equimolar dose of cPTI, or vehicle (saline) was started 10 min before intravenous lipopolysaccharide (LPS) injection (20 mg/kg, Escherichia coli serotype O111:B4; Sigma). Infusion of cPTIO, cPTI, or vehicle was maintained throughout the experiment. For plasma level determinations, a blood sample was taken from the cannulated carotid artery 5 min before the start of the cPTIO infusion. Blood samples were then taken at the indicated times after the LPS administration. All samples were collected and placed in Eppendorf tubes containing 10 mM final concentration indomethacin (Sigma) and 0.129 M citrate as anticoagulant. Blood samples were immediately centrifuged at 13,000 g for 5 min, and plasma samples were stored at Ϫ80ЊC until analysis. After experimentation, rats were killed by exsanguination.
Measurement of plasma concentration of prostanoids. Preparation of aorta rings. After removal, the aorta was dissected free of connective tissue and cut into ∼5-mg rings. The aorta rings were then incubated in RPMI culture medium containing 200 mM acetylsalicylic acid (aspirin) at 37ЊC for 20 min. The medium containing aspirin was removed before the PGIS activity assay.
Lung homogenate preparation. After removal, lungs were frozen in liquid nitrogen and were stored at Ϫ80ЊC until use. They were mechanically homogenized in 10 mM Hepes (pH 7.2) containing 320 mM sucrose, 0.1 mM EDTA, 1 mM dithiothreitol, 10 mg/mL leupeptin, 2 mg/mL aprotinin, 10 mg/mL trypsin inhibitor, and 100 mg/mL phenylmethylsulfonylfluoride, with a Potter-Elvehjem device placed in an ice-water bath. The homogenate was centrifuged at 8000 g for 30 min; the supernatant was collected, was treated with 200 mM aspirin in RPMI medium at 37ЊC for 20 min, and was centrifuged at 100,000 g for 90 min. The pellet was resuspended in 100 mM Tris-HCl (pH 8.5) containing 2 mM phenol. The protein content was measured by Bradford's method, using the Bio-Rad protein assay, and was adjusted to 200 mg of protein/100 mL.
PGIS activity measurement. PGIS activity in aorta rings or lung homogenates was determined as described elsewhere [1] , with small modifications. We incubated 100 U of COX-1 from ram seminal vesicles (Cayman Chemical) in 100 mM Tris-HCl (pH 8.5) containing 2 mmol/L phenol (200 mL, aorta rings; 100 mL, lung homogenates) with [ 14 C]AA ([1-
14
C]AA; 55-58 mCi/mmol [Amersham Ibérica]; final concentration in incubation with tissues, 25 mM) at 30ЊC for 1 min. We added the aspirin-treated aorta ring or 100 mL of aspirin-treated lung homogenate to the COX preparation, and the mixture was incubated for 5 min at 37ЊC. The reaction was stopped by adding 350 mL of methanol:water:acetic acid (550: 150:11).
14 C-labeled 6-oxo-PGF 1a was evaluated by high-performance liquid chromatography, as described elsewhere [22] . The quantity of COX-1 necessary to guarantee generation of a excess 14 C-labeled endoperoxidase was determined in previous experiments by testing different amounts of isolated COX-1. 6-oxo-PGF 1a was only observed when tissue was present in the preparation and the production of 6-oxo-PGF 1a , using 50 U COX-1 per incubate, was maximal ( ); 100 U of COX was chosen for the study. n p 5 NOS activity measurement. Rats were killed at the indicated times after administration of LPS, and NOS activity was quantified in lung homogenates by measuring the conversion of L- Specific inducible NOS (iNOS) mRNA analysis. Rats were killed at the indicated times after administration of LPS or vehicle, and iNOS mRNA was quantified in lung homogenates. Total RNA was isolated by the Ultraspec isolation system (Biotecx Laboratories). Lungs were mechanically homogenized in Ultraspec buffer. The specific mRNA levels were estimated by a quantitative reverse transcription-polymerase chain reaction (RT-PCR) protocol. RNA (5 mg) was reverse-transcribed by incubation with 75 U of murine leukemia virus reverse transcriptase in a reaction buffer containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 5 mM MgCl 2 , 0.4 mM antisense primer (described later), 30 U of RNAase inhibitor, and 1 mM dNTPs (Pharmacia Biotech) in a final volume of 30 mL (all from Perkin-Elmer unless indicated). The reaction mixture was incubated for 30 min at 42ЊC, stopped by heating for 5 min at 99ЊC, and cooled for 5 min at 5ЊC. The PCR was carried out in a DNA thermal cycler (model 480; Perkin-Elmer) with a reaction mixture (100 mL) containing 8 mM Tris-HCl (pH 8.3), 40 mM KCl, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.4 mM sense/antisense primers, 2.5 U Taq polymerase, and 4 mCi [ . Serial half dilutions of the cDNA were made to test linearity. The primers (Progenetic SL) used for iNOS were 5 -CACAAGGCCACATCG-GATTTC-3 (sense) and 5 -TGCATACCACTTCAACCCGAG-3 (antisense) [25] . The RNA for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was amplified and used as the internal control. The sense and antisense primers used for GAPDH were 5 -TCCCTCAAGATTGTCAGCAA-3 and 5 -AGATCCACAACG-GATACATT-3 , respectively [26] . Thirty cycles were done as follows: 1 min at 95ЊC, 1 min at 55ЊC, and 2 min at 72ЊC for all samples. The amplification products were separated by electrophoresis in a 1.5% wt/vol low-melting-point agarose gel containing ethidium bromide. Radioactivity associated with the specific band was evaluated as described elsewhere [27, 28] . The radioactivity was normalized with respect to GAPDH.
Effect of an NO donor and NOS inhibitor in the presence or absence of cPTIO on PGIS activity in vitro.
Under sterile conditions, aortas from untreated rats were cleared of periadventitial connective tissue and cut into ∼3-mg rings. Rings were placed in sterile 24-well plates containing 1 mL of RPMI containing 2 mM glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1% fetal bovine serum. To this medium, we added the following compounds: none, 100 mM SNAP (NO donor), 100 mM cPTIO, 100 mM cPTI, 100 mM SNAP plus 100 mM cPTIO, 100 mM SNAP plus 100 mM cPTI, 1 mM L-NMMA or 100 mM cPTIO plus 1 mM L-NMMA. Aorta rings were then incubated at 37ЊC for 4 h in a 5% CO 2 atmosphere. After medium was recovered for nitrite/nitrate evaluation, aorta rings were incubated with [ 14 C]-labeled endoperoxidase, to determine PGIS activity.
Statistics. We used Sigma-Stat software (SPSS Science) for statistical analysis. Statistical significance between groups was assessed by Student's t test for 2 groups. One-way analysis of variance and the Student-Newman-Keuls tests were used to compare 12 groups.
was considered significant. P ! .05
Results

MAP and survival in normal rats and in rats treated with LPS
or with LPS plus cPTIO. Administration of cPTIO alone caused a slight increase in MAP, particularly during the first 2 h, without any significant effect on survival during the observation period ( figure 1 ). This increase was not due to volume loading during the infusion, because infusion of vehicle did not cause significant variation of MAP (not shown). Time-dependent hypotension was observed in LPS-treated rats, as shown by a double wave-shaped MAP curve ( figure 1A) . The first phase of LPS-treated rats at р2 h after LPS infusion was similar to that of rats treated with LPS plus cPTIO. In a second phase, ; not shown) n p 15 Expression of iNOS and NOS activity in rats treated with LPS. As expected, administration of LPS produced a substantial time-dependent elevation of NOS activity in lung homogenates (figure 2). There was also a time-dependent induction of iNOS in terms of mRNA steady-state levels in lung homogenates. mRNA for iNOS increased until 3 h after LPS administration and then decreased. NOS activity increased throughout the observation period.
Nitrite/nitrate plasma levels. Consistent with the NOS activity results, LPS induced a time-dependent increase of plasma levels of nitrite/nitrate, with values similar to those found in rats treated simultaneously with LPS and cPTIO ( figure 3) .
Prostanoid plasma levels. Figure 4 depicts plasma levels of 6-oxo-PGF 1a (stable metabolite of PGI 2 ), TxB 2 (stable metabolite of TxA 2 ), and PGF 2a . LPS administration caused an increase of the 3 prostanoids analyzed. Rats treated with LPS and cPTIO exhibited prostanoid plasma levels similar to those treated with LPS, with the exception of 6-oxo-PGF 1a . After 3 h of LPS administration, levels of 6-oxo-PGF 1a were lower in the rats treated with LPS plus cPTIO, although differences in the LPS treatment group only reached statistical significance 4 h after LPS injection. These results suggested a selective inhibitory action of cPTIO on PGIS activity. To rule out the possibility that the effect of cPTIO on 6-oxo-PGF 1a was due to cPTI formation, rats were infused with cPTIO equimolar dose of cPTI and treated with LPS. Plasma levels of 6-oxo-PGF 1a were then measured ( ): No differences were observed n p 4 when compared with the LPS group (not shown).
PGIS activity ex vivo. After 4 h of LPS administration, PGIS activity was evaluated in lung homogenates and aorta rings (see Methods). As shown in figure 5 , the loss of PGIS activity was not identical in these tissues. PGIS activity in lung homogenates of LPS-treated rats was lower than in controls, but this difference was not significant when evaluated in the aorta rings. In the animals treated with cPTIO, the PGIS activity was significantly lower than in control rats, although this was more pronounced in lung homogenates than in aorta rings. The lowest PGIS activity was found in samples from rats treated with both cPTIO and LPS. As shown in figure 5, there were no significant differences in PGIS activity ex vivo between LPS-treated rats and LPS-treated rats infused with cPTI.
Effect of NO donor and NOS inhibitor in the presence or absence of cPTIO on PGIS activity in vitro.
The above results suggested that NO 2 , generated by the reaction of cPTIO with NO, inhibited PGIS. Thus, we incubated aorta rings from untreated rats for 4 h in a culture incubator with culture medium or medium containing 100 mM of SNAP (NO donor), 100 mM cPTIO, or both. Results are shown in figure 6A . SNAP did not exert any effect on PGIS activity, whereas cPTIO significantly inhibited the enzyme. When aorta rings were incubated with both cPTIO and SNAP, PGIS activity was significantly more inhibited than when incubated with cPTIO alone. L-NMMA alone did not affect ; all others, ). mean ‫ע‬ SD n p 4 n p 7 PGIS activity. Nevertheless, when it was present in the incubation medium with cPTIO, L-NMMA abolished the inhibitory effect of cPTIO on PGIS activity. We found no significant effect of cPTI alone or in combination with SNAP on PGIS activity in vitro. As shown in figure 6B , the presence of SNAP increased nitrite/nitrate levels in the medium, indicating a higher formation of NO. Nitrite/nitrate levels in the medium were significantly lower in the presence of L-NMMA than in controls.
Discussion
This study was undertaken to observe the action of cPTIO on PGIS activity, extending our previous in vitro research that suggested an inhibitory action of NO 2 on PGIS endothelial cells in vitro [1] . Yoshida et al. [17] found that cPTIO had a therapeutic value in experimental endotoxic shock. By using the most effective dose used by Yoshida et al., we observed a clear improvement in the MAP fall and a significant reduction in mortality caused by the administration of LPS in the rats given cPTIO in addition to LPS. Even though our administration protocol of cPTIO differed from that of Yoshida et al. [17] , our results confirm their findings. Our results are also consistent with other reports suggesting that inhibition of excess of NO could be beneficial in shock (reviewed in [4, 5, 29, 30] ).
We evaluated iNOS and NOS activity in the lung, which is one of the most affected organs in systemic inflammation syndromes. Our results with lung homogenates were consistent with those reported by Liu et al. [31] , who analyzed heart, lung, and aortic and pulmonary arteries; iNOS expression and NOS activity were increased by the administration of LPS, which resulted in enhanced circulating levels of nitrite/nitrate. Nevertheless, NOS activity was significantly increased after 3 h of LPS administration, whereas the increase in nitrite/nitrate levels was observed just 1 h after LPS injection, indicating that, during the first phase of the syndrome, the MAP decline was due to NO coming from constitutive NOS, rather than from iNOS. This concept is supported by data reported by others (reviewed in [29] ). As expected, no effect of cPTIO on nitrite/nitrate levels was observed because NO 2 can easily be transformed into nitrite [32] .
Also consistent with previously reported data [7] , increased circulating levels of prostanoids were observed in LPS-treated rats. LPS increased plasma levels of 6-oxo-PGF 1a , TxB 2 , and Figure 6 . Effect of nitric oxide (NO) donor and nitric oxide synthase (NOS) inhibitor in presence or absence of 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (cPTIO) on prostacyclin synthase (PGIS) activity (A) and nitrite/nitrate levels (B) in vitro. Rings were incubated in medium with none (control), 100 mM NO donor (SNAP), 100 mM cPTIO, 100 mM SNAP ϩ 100 mM cPTIO, 100 mM 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl (cPTI), 100 mM SNAP ϩ 100 mM cPTI, 1 mM L-N G -monomethyl arginine (L-NMMA), or 100 mM cPTIO ϩ 1 mM L-NMMA at 37ЊC in 5% CO 2 atmosphere for 4 h. Nitrite/nitrate levels were determined in incubation medium and PGIS activity in aorta rings. Bars are ( mean ‫ע‬ SD n p , controls;
, all others). 10 n p 5 PGF 2a by 1 h after LPS injection. In rats exposed to LPS, cPTIO did not significantly modify prostanoid levels, except for 6-oxo-PGF 1a levels, which were inhibited after 3 h of LPS injection, suggesting a specific progressive action of cPTIO on PGI 2 synthesis.
Results of the PGIS activity analysis 4 h after LPS injection indicated that LPS partially inactivated PGIS in lung homogenate samples. This was not so evident in the aorta rings. These results are consistent with findings from in vitro experiments in which exposure of endothelial and mesangial cells to a potent proinflammatory stimulus (e.g., IL-1b) partially inactivated PGIS [1, 11] . Administration of cPTIO significantly reduced PGIS activity in both aorta rings and lung homogenates: The effect was more relevant in the latter. Administration of both LPS and cPTIO reduced PGIS activity to a greater extent than LPS alone. The effect of cPTIO on 6-oxo-PGF 1a plasma levels and on PGIS activity was not likely coincident, because many organs and cell types contributed to plasma levels and because the effect of LPS and cPTIO probably was not uniform in different tissues, as indicated by tissue analysis results. Although the inhibitory effect of cPTIO on 6-oxo-PGF 1a plasma levels and on PGIS activity are not coincident, they are consistent with one another.
The final vascular constriction or relaxation is the result of the balanced action of constricting and relaxing agents. Definitive evaluation of the exact importance of PGI 2 and, hence, the PGIS activity in the decline of blood pressure and mortality in endotoxemia should be obtained using specific PGIS inhibitors or PGI 2 antagonists without altering other vasoactive agents. Nevertheless, as far we know, this is not yet possible. By using COX-2 selective inhibitors at doses that inhibited PGI 2 formation, Leach et al. [33] observed an increase in the hypotension induced by LPS injection. We obtained similar results when we administered indomethacin or COX-2 selective inhibitors at doses that inhibited 6-oxo-PGF 1a , TxB 2 , and PGF 2a by 180% (unpublished data). Leach et al. concluded that the increase in prostanoid formation does not contribute to the circulatory failure caused by LPS; however, they only determined plasma levels of 6-oxo-PGF 1a , and the other prostanoids that have vasoconstricting activity were probably inhibited by the COX-2 inhibitors. Inhibition of COX leads to the inhibition of both relaxing and constricting prostanoids and may alter production of other vasoactive agents that are regulated by prostaglandins, such as the renin-angiotensin system. In contrast, we observed that cPTIO selectively inhibited PGIS without modifying synthesis of other prostanoids in the LPS-induced shock.
The results of the in vitro experiments showed that NO alone did not exert any effect on PGIS since SNAP significantly increased nitrite/nitrate in the culture medium without appreciable modification of PGIS activity. In contrast, cPTIO decreased PGIS activity, an effect that was even more pronounced when both SNAP and cPTIO were present in the culture me-dium. L-NMMA, which inhibited NO formation, consistently abolished the effect of cPTIO. The fact that cPTI alone or in combination with SNAP did not modify the PGIS activity in aorta rings incubated in vitro rules out the possibility that cPTI, the other product of the reaction of NO with cPTIO, was involved in the inactivation of PGIS by cPTIO. Thus, when NO was removed from cPTIO, PGIS was not inactivated even when NO was supplied. Collectively, these results indicate that NO 2 derived from NO could be responsible, at least in vitro, for the PGIS inactivation caused by cPTIO.
Several sources of NO 2 could exist in vivo. NO reacts with oxygen in air to yield NO 2 , NO and NO 2 achieving equilibrium. In an aqueous solution, NO combines with molecular oxygen to form NO 2 with a reaction velocity 2 orders of magnitude higher than in the gaseous phase [34] . NO 2 could be formed by oxidation of nitrite through the action of mammalian peroxidases [35, 36] . NO reacts with superoxide anion to form peroxynitrite [37] . Homolytic fission of peroxynitrous acid, formed by protonation of peroxynitrite, yields NO 2 and hydroxyl radical [12, 13] . Zou et al. [14] found that nitration of an active site-related tyrosine could account for the in vitro PGIS inactivation caused by peroxynitrite [10, 11] . They proposed an O-O homolytic cleavage in the peroxynitrite molecule caused by the heme-iron of the PGIS. This could yield NO 2 ϩ nitrating species that might attack tyrosine or tyrosinate [14] . Nevertheless, nitration of tyrosyl residues by NO 2 is also possible by means of the formation of tyrosyl radicals [18] [19] [20] . Of note, we were unable to demonstrate PGIS nitration because commercial antibodies against PGIS did not run well in our rat samples.
Cigarette smoke is one of the greatest exogenous sources of human exposure to NO [38, 39] . NO is converted to NO 2 within minutes and nitrogen oxides in the gas-phase of the cigarette smoke nitrate tyrosine [40] . Hong et al. [41] reported that AA metabolite(s) of the COX pathway is involved in the late phase of cigarette smoke-induced bronchoconstriction but did not identify the COX-derived compound involved in the bronchoconstriction. Our results allow us to speculate that an increased amount of PGH 2 released by vascular endothelium caused by NO 2 -dependent partial inactivation of PGIS could account for the observations of Hong et al. Also, cigarette smoke impairs endothelium-dependent relaxation [42] , and selective nitration of PGIS in atherosclerotic bovine coronary arteries has been reported elsewhere [43] . Ex vivo, hypoxia-reoxygenation generates peroxynitrite that inactivates PGIS, causing PGH 2 -mediated coronary vasospasm in isolated bovine coronary arteries that depend on PGH 2 accumulation [44] . In vivo and ex vivo data reported by Zou and coworkers [43, 44] show that inhibition of PGIS is relevant in vascular response. In vivo data clearly indicate that, in atherosclerotic lesions in which nitrated PGIS was detected, formation of PGI 2 was reduced, and impaired vasorelaxation was observed [43] . Impaired vasorelaxation was corrected in the presence of a TxA 2 /PGH 2 antagonist, whereas inhibition of TxA synthase was ineffective. Laboratory data strongly suggest that, when vascular PGIS is inhibited, the vasoconstrictor PGH 2 is released [43, 44] .
In summary, our results show that cPTIO selectively reduces PGI 2 formation and PGIS activity in vivo and in vitro when NO is supplied and cPTI does not exert any action on PGIS activity. Although our results are not conclusive with respect to the exact mechanism by which cPTIO plus NO inactivate PGIS, they are consistent with the concept that NO 2 (or a related compound) derived from NO could be involved in the PGIS inactivation caused by cPTIO. Chemical studies that include detection of nitrated PGIS will be performed to confirm such a mechanism. Our results are consistent with the hypothesis that selective inhibition of PGIS could contribute, in addition to NO scavenging, to the beneficial effect of cPTIO in experimental shock by reducing the formation of the potent vasodilator PGI 2 . More research is needed to clarify the physiologic sources of NO 2 and the exact relevance of PGI 2 inhibition in physiopathologic situations in which NO formation is increased, such as chronic inflammation, systemic inflammatory syndromes, or atherosclerosis.
